Cell therapy (TCR-T) · Kills target cells, directed at tumor-associated antigen · developed by Cogent Biosciences
ACTR087 is an autologous T-cell therapy genetically modified to express an antibody-coupled T-cell receptor (ACTR) containing CD16, 4-1BB, and CD3 zeta domains. When co-administered with a cancer-specific antibody, it recognizes tumor-associated antigens and kills tumor cells through cytotoxin release, cytokine production, and T-cell proliferation. It is studied in lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02776813 | Phase 1 | Lymphoma | Completed | COGT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lymphoma
See COGT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
COGT catalysts and pipeline →